(177)Lu-PSMA Articles

Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) radioligand therapy is an option that is increasingly being used for treatment of metastatic castration-resistant prostate cancer. This delivers β-radiation to cells expressing PSMA and high accumulation of the radiopharmaceutical occurs in the kidneys.

Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-Dotatate for neuroendocrine tumors, and 177Lu-PSMA for prostate cancer, and several more under investigation.